Multiple Sclerosis CD3+ T Cells

About Multiple Sclerosis CD3+ T Cells

Multiple Sclerosis CD3+ T Cells for Autoimmune Demyelination Research

Multiple Sclerosis CD3+ T Cells are isolated from the peripheral blood of IRB-consented adult donors diagnosed with multiple sclerosis (MS). Multiple sclerosis is an autoimmune disease in which lymphocytes cross the blood-brain barrier and attack myelin in the central nervous system, producing demyelinating lesions and progressive neuroaxonal loss. These CD3+ enriched T lymphocytes support investigation of T cell phenotype, trafficking, cytokine production and exhaustion in the cell type central to that process.

Why CD3+ T Cells for Multiple Sclerosis Research

• T cells are the effector population in MS. Myelin-reactive CD4+ Th1 and Th17 cells initiate lesion formation, while CD8+ T cells predominate numerically within established plaques — a pan-CD3 preparation captures both arms in their donor-native proportions.
• The disease is defined by lymphocyte trafficking into the CNS. Alpha-4 integrin (VLA-4), the target of natalizumab, mediates adhesion and transmigration across the blood-brain barrier, and adhesion and migration assays require intact viable T cells rather than a soluble specimen.
• Sphingosine-1-phosphate receptor modulators act by sequestering lymphocytes in lymphoid tissue, preventing egress into the circulation and the CNS. S1P receptor expression and receptor internalisation assays are performed directly on patient T cells.
• T cell receptor repertoire sequencing in MS addresses clonal expansion and antigen specificity questions; starting from a CD3-enriched population removes B cell and myeloid background and improves depth for a given sequencing budget.
• Th17 polarisation, GM-CSF production and regulatory T cell suppressive capacity are all functional readouts studied in MS that require live cells and defined stimulation, not measurement of circulating cytokines.
• Starting from pre-enriched CD3+ cells removes an isolation step and the associated activation and loss, which matters for phospho-signalling and other time-sensitive functional assays.

Donor Stratification Available

• MS subtype: relapsing-remitting, secondary progressive, or primary progressive where classified
• Disability by EDSS score where recorded
• Clinical state at collection: active relapse versus clinical remission
• Disease-modifying therapy status: treatment-naive, on anti-CD20 therapy, on S1P receptor modulator, on natalizumab, on interferon beta or glatiramer acetate, on oral agent, or in washout
• Disease duration and age at onset
• MRI lesion activity where reported
• Matched healthy controls available

Product Features

• Research Use Only (RUO), CD3+ enriched T cells
• Isolated from clinically confirmed multiple sclerosis donors
• Purity, viability and recovery values reported per lot
• Cryopreserved in CryoStor® CS10 media
• Processed within 24 hours of collection
• Custom aliquot sizes available on request
• IRB-approved collection and HIPAA-compliant handling

De-identified Donor Data

• Confirmed multiple sclerosis diagnosis
• Demographics: age, sex assigned at birth, race/ethnicity
• Clinical history and medication records available
• Subtype, disease duration and therapy status where available

Applications

• T cell subset immunophenotyping and immune profiling in multiple sclerosis
• Adhesion, migration and transmigration assays relevant to blood-brain barrier crossing
• S1P receptor expression and internalisation studies for disease-modifying therapy mechanism
• T cell receptor repertoire sequencing and clonality analysis
• Th17 polarisation, cytokine production and exhaustion marker studies
• Regulatory T cell frequency and suppressive function assays
• Target validation and preclinical drug development in autoimmune neurology
• Cell therapy and immune modulation modelling

Other Multiple Sclerosis Specimen Types

• Multiple Sclerosis PBMC
• Multiple Sclerosis Leukopak
• Multiple Sclerosis Serum
• Multiple Sclerosis Plasma
• Multiple Sclerosis Whole Blood
• Multiple Sclerosis Cerebrospinal Fluid
• Multiple Sclerosis CD4+ T Cells and CD8+ T Cells

Compliance and Quality Assurance

• IRB-approved protocols and 21 CFR Part 11-compliant e-consent
• Standardized isolation and cryopreservation
• HIPAA-compliant data protection and donor confidentiality

Ordering & Customization

Multiple Sclerosis CD3+ T Cells are available in standard or custom aliquot sizes. For pricing, availability, or to discuss a cohort stratified by subtype or therapy status, contact learnmore@sanguinebio.com. For international shipments or documentation, please contact us to confirm regional compliance. To browse PBMCs and isolated cell products across all disease states, visit our human PBMC page.